Keros Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Keros is a clinical-stage biopharmaceutical company developing therapies for disorders linked to TGF-β signaling. It has no approved products and has not generated product-sales revenue.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $0.083 million | None |
| Research and development expense | $38.3 million | $31.1 million; up $7.2 million |
| General and administrative expense | $10.3 million | $7.8 million; up $2.5 million |
| Operating loss | $48.5 million | $38.9 million |
| Net loss | $43.1 million | $35.8 million |
| Net loss per share | $1.21 | $1.26 |
| Operating cash used | $44.6 million | $34.2 million |
Revenue was service revenue from the Hansoh manufacturing technology-transfer work; no product revenue was recorded. Other income was $5.4 million, including $5.8 million of dividend income, compared with $3.1 million of other income in Q1 2023. The filing does not provide a meaningful product gross margin; Keros remains loss-making.
Cash and cash equivalents were $442.4 million at March 31, 2024, versus $331.1 million at December 31, 2023. Cash, cash equivalents and restricted cash totaled $443.7 million. Financing cash flow was $156.8 million, primarily from the January 2024 public offering, which generated approximately $151.1 million net, and $5.7 million from option exercises. Investing cash use was $0.9 million. The company reported no debt outstanding. Total liabilities were $31.9 million and stockholders’ equity was $453.9 million.
Material changes and business developments
- Net loss increased by $7.3 million year over year. R&D expense rose chiefly with KER-065 development and higher personnel costs; KER-050 expense declined as manufacturing and preclinical costs fell, partly offset by greater clinical spending.
- G&A expense increased primarily from personnel and professional costs. Stock-based compensation was $8.1 million, up from $5.7 million.
- The January offering issued 4.025 million shares at $40 per share. Shares issued and outstanding rose to 36.1 million at quarter-end from 31.8 million at year-end 2023.
- Keros deprioritized KER-047 in 2023 and is no longer separately reporting its costs in 2024.
Outlook, risks and unusual items
- Management expects continued operating losses and negative operating cash flows as it advances its pipeline. It expects R&D spending to fluctuate with clinical, manufacturing and development activity.
- Clinical milestones described include additional KER-050 MDS and myelofibrosis Phase 2 data in Q2 and Q4 2024, and a planned Phase 3 MDS trial-design update in mid-2024; a KER-012 PAH enrollment update in the first half of 2024 and heart-failure biomarker data in the second half; and initial KER-065 Phase 1 data in Q1 2025. These are forward-looking expectations, not reported results.
- The filing gives inconsistent cash-runway statements: the liquidity discussion says existing cash supports operations for at least the next 12 months, while the risk factors say cash as of March 31 is expected to fund operations into 2027. Management cautions that estimates depend on assumptions and spending could be faster than expected.
- Key risks include clinical-trial safety, efficacy, enrollment and timing; reliance on third-party manufacturers and CROs, including single-source manufacturing for each lead candidate; competition; intellectual-property and regulatory risks; and the need for additional capital over time. The filing notes Merck’s March 2024 FDA approval of sotatercept for PAH and increased competition in Keros’s target areas.
- The Hansoh agreement provides potential development milestones of up to $26.5 million, sales milestones of up to $144.0 million and tiered royalties, but no milestones had been achieved by March 31, 2024. Keros recognized $0.1 million of technology-transfer service revenue in the quarter.
- No material legal proceedings were reported. Management concluded disclosure controls were effective at the reasonable-assurance level; no material change in internal control over financial reporting was reported.
Most important facts for investors to verify
- Reconcile the stated cash runway: “at least 12 months” in the liquidity discussion versus “into 2027” in the risk factors.
- Track clinical-trial progress, data quality and safety for KER-050, KER-012 and KER-065 against the stated timelines, and assess how results could affect spending.
- Monitor quarterly operating cash burn, R&D cost growth and whether financing or collaboration proceeds are needed; the January offering also increased the share count.
- Confirm the remaining ATM capacity (reported as $71.5 million at March 31, 2024) and consider potential dilution from future equity issuance and outstanding equity awards.
- Assess reliance on single-source manufacturers, the status of the Hansoh technology transfer, and competitive developments in MDS, myelofibrosis, PAH and obesity.